A revolution in breast cancer diagnostics and the design of personalized treatment

Multiplex8+ uses breakthrough RNA quantification technology to provide accurate and reliable results, giving oncologists, and healthcare providers the confidence they need.

About the test

Multiplex8+ is a cutting-edge diagnostic test for breast cancer (BCa) patients, that uniquely predicts treatment efficacy across multiple therapeutic approaches, including chemotherapy, immunotherapy, and antibody drug conjugates (ADCs). By identifying a broad spectrum of biomarkers, Multiplex8+ enables highly personalized treatment.

Multiplex8+ is a research use only (RUO) diagnostic test with published validation. 

Additional clinical validation of Multiplex8+ is ongoing.

Key features of Multiplex8+:

  • Comprehensive analysis of over 20,000 tumor-specific biomarkers and 200+ genes/gene signatures to predict treatment response
  • Cross-validation of key markers with two quantitative methods (RNA-SEQ and RNA-FISH), minimizing diagnostic errors
  • Personalized report with treatment associations, including molecular profiling and relevant gene signatures for individualized treatment and prognosis
  • Can inform second opinions
  • Is relevant for all stages of the cancer journey
  • Detection of tumor heterogeneity for a more accurate understanding of the cancer's profile
  • Results within 3 to 4 weeks
  • Utilizing existing biopsy or surgical resection samples

Together, these features make Multiplex8+ a promising tool for identifying the most effective and personalized treatment options for every BCa patient.

What does Multiplex8+ provide?

Personalization

Each report is explained and tailored to the unique clinical parameters of the patient enabling true personalized diagnostics and treatment.

Accuracy

The gene expression of the 4 main BCa biomarkers is quantified and crossvalidated by 2 independent methods for exceptional precision and 93% accuracy.

Granularity

Classification of the tumor into one of the 4 molecular subtypes and 6 TNBC subtypes provides the deepest insights into tumor biology.

Prognosis

By profiling 20,000 genes and 100+ gene signatures, Multiplex8+ predicts sensitivity to treatments (e.g., ADCs), risk of recurrence,  and characterizes activity of the major cancer hallmark pathways.

Conclusiveness

The report provides an unambiguous diagnostic information and a foundation for treatment decisions fostering confidence for patients and medical professionals.

Multiplex8+ Offers Unique Insights into Your Patient

An innovative and efficient BCa diagnostics tool with superior accuracy and broad potential.

  1. RNA-FISH detects expression of 4 key clinical biomarkers on a single tissue section and serves as a powerful tool to interrogate tumor heterogeneity.
  2. QUANTITATIVE ANALYSIS of RNA-FISH leveraging AI-based software identifies regions of interest/ heterogeneous regions that and annotated for downstream spatial transcriptomics.
  3. TOTAL RNA-SEQUENCING and QUANTITATIVE ANALYSIS provides unbiased tumor-specific profiling of all 20 000+ protein-coding and non-coding genes, including 175+ therapy predictive and prognostic genes.
  4. FISH-GUIDED
    LASER CAPTURE MICRODISSECTION isolates distinct regions of interest and ensures tumor enrichment in the sample by eliminating contamination from non-tumor elements.

Multiplex8+ provides actionable results 

The figure below shows test results for 74 clinical patients, who comprised all treatment settings and molecular subtypes.

Multiplex8+ was validated on 1082 patient samples. For more details on our innovative mFISHseq platform, including findings on tumor profiling, immunotherapy response, and targeted therapies, please explore our manuscript "The Spatially Informed mFISHseq Assay Resolves Biomarker Discordance and Predicts Treatment Response in Breast Cancer," published in Nature Communications.

Deployment of Multiplex8+ as a research-use only (RUO) test. (a) Table outlining the number of genes and gene signatures and their relevant drug targets/pathways that were used for clinical testing. (b) Proportion of 74 patients according to treatment setting (left bar), molecular subtype (middle bar), and TNBC subtype (right bar). (c) Frequency of therapies that were recommended as the top 3 according to expression of genes and gene signatures tailored to each of the 74 patients. (d-h) Expression of 20 ADC antigen targets (d), targets relevant to payloads for topoisomerase and microtubule inhibitors (e), endocytosis targets involved in internalization of ADCs (f), lysosome targets involved in degrading antibodies and linkers (g), and targets that confer resistance to ADCs (h). (i) Combinations of these ADC-processing gene targets and signatures can be used to identify patients that are more likely to respond to ADCs like Trodelvy (SG) (Patient 1), Enhertu (T-DXd) (Patient 18), and Trodelvy, Enhertu and Kadcyla (T-DM1) (Patient 15), or those who are less likely to respond because they lack ADC-predictive biomarkers (Patient 23).


Case Studies

Multiplex8+ report provides a guide for a tailored treatment plan.

Number of patients:
148

Patient 148 Report
Patient 147 Report
Patient 146 Report
Patient 145 Report
Patient 144 Report
Patient 143 Report
Patient 142 Report
Patient 141 Report
Patient 140 Report
Patient 139 Report
Patient 138 Report
Patient 137 Report
Patient 136 Report
Patient 135 Report
Patient 134 Report
Patient 133 Report
Patient 132 Report
Patient 131 Report
Patient 130 Report
Patient 129 Report
Patient 128 Report
Patient 127 Report
Patient 126 Report
Patient 125 Report
Patient 124 Report
Patient 123 Report
Patient 122 Report
Patient 121 Report
Patient 120 Report
Patient 119 Report
Patient 118 Report
Patient 117 Report
Patient 116 Report
Patient 115 Report
Patient 114 Report
Patient 113 Report
Patient 112 Report
Patient 111 Report
Patient 110 Report
Patient 109 Report
Patient 108 Report
Patient 107 Report
Patient 106 Report
Patient 105 Report
Patient 104 Report
Patient 103 Report
Patient 102 Report
Patient 101 Report
Patient 100 Report
Patient 99 Report
Patient 98 Report
Patient 97 Report
Patient 96 Report
Patient 95 Report
Patient 94 Report
Patient 93 Report
Patient 92 Report
Patient 91 Report
Patient 90 Report
Patient 89 Report
Patient 88 Report
Patient 87 Report
Patient 86 Report
Patient 85 Report
Patient 84 Report
Patient 83 Report
Patient 82 Report
Patient 81 Report
Patient 80 Report
Patient 79 Report
Patient 78 Report
Patient 77 Report
Patient 76 Report
Patient 75 Report
Patient 74 Report
Patient 73 Report
Patient 72 Report
Patient 71 Report
Patient 70 Report
Patient 69 Report
Patient 68 Report
Patient 67 Report
Patient 66 Report
Patient 65 Report
Patient 64 Report
Patient 63 Report
Patient 62 Report
Patient 61 Report
Patient 60 Report
Patient 59 Report
Patient 58 Report
Patient 57 Report
Patient 56 Report
Patient 55 Report
Patient 54 Report
Patient 53 Report
Patient 52 Report
Patient 51 Report
Patient 50 Report
Patient 49 Report
Patient 48 Report
Patient 47 Report
Patient 46 Report
Patient 45 Report
Patient 44 Report
Patient 43 Report
Patient 42 Report
Patient 41 Report
Patient 40 Report
Patient 39 Report
Patient 38 Report
Patient 37 Report
Patient 36 Report
Patient 35 Report
Patient 34 Report
Patient 33 Report
Patient 32 Report
Patient 31 Report
Patient 30 Report
Patient 29 Report
Patient 28 Report
Patient 27 Report
Patient 26 Report
Patient 25 Report
Patient 24 Report
Patient 23 Report
Patient 22 Report
Patient 21 Report
Patient 20 Report
Patient 19 Report
Patient 18 Report
Patient 17 Report
Patient 16 Report
Patient 15 Report
Patient 14 Report
Patient 13 Report
Patient 12 Report
Patient 11 Report
Patient 10 Report
Patient 9 Report
Patient 8 Report
Patient 7 Report
Patient 6 Report
Patient 5 Report
Patient 4 Report
Patient 3 Report
Patient 2 Report
Patient 1 Report

How to order

To order, please contact us at diagnostics@multiplexdx.com to request an order form

We are dedicated to supporting you throughout the ordering process for our innovative breast cancer RUO diagnostic test Multiplex8+. Our team is committed to providing guidance and assistance to ensure a seamless experience with our test. We will provide support to facilitate the ordering procedure and provide information regarding our diagnostic test.

Send Message to diagnostics@multiplexdx.com
or call +421 947 904 001

About MultiplexDX

MultiplexDX is one of the most innovative biotech companies, headquartered in Bratislava, Slovakia, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. It was founded in 2016 by Dr. Pavol Cekan who has extensive experience in the fields of biotechnology research in EU and US ecosystems. The company operates in the Science Park of Comenius University and has a dedicated international team of 30 people, complemented by the expertise of our top-level advisory board consisting of world-renowned 2 scientific and 2 business advisors. MDX has achieved remarkable success since its foundation. The company has received numerous awards. It was also recognized as one of the 2017 New Europe 100 Challengers by the Financial Times, Google, and Visegrad Fund. MDX‘s journey includes participation in top-tier accelerators such as the Health Hub Vienna Acceleration Program for biotech start-ups and membership in the Oslo Cancer Cluster. In 2019, MDX became the first SK company in history to be awarded the prestigious EIC Accelerator in which it successfully validated its innovative technology in a large-scale retrospective validation on 1,080 breast tumors. In 2022, MDX achieved a significant milestone by ranking 1st in the TOP3 of the Deloitte Fast 50 CEE. In 2023, the company provided its first personalised results for breast cancer patients and signed the first MoUs with oncology institutes in SK. In 2023, MDX was chosen among only 47 EU companies and only 10 SMEs, to be part of the Global Gateway Business Advisory Group to assist the European Commission. In 2024 and 2025, MDX published its research and results from retrospective clinical studies in the prestigious peer-reviewed scientific journal, Nature Communications. For more recent updates, please visit our website. 

Declaration: MultiplexDX, s.r.o. declares that the Multiplex8+ test is only manufactured and used in MultiplexDX, s.r.o. and meet the applicable general safety and performance requirements (GSPR) of the in vitro diagnostic medical devices Regulation (EU 2017/746).  /  Declaration.pdf

// Jednoduché doplnenie prázdnych fake slide-ov na konci